866-997-4948(US-Canada Toll Free)

Q Fever - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 41 Pages

Q Fever - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Q Fever Pipeline Review, H2 2016, provides an overview of the Q Fever (Infectious Disease) pipeline landscape.

Q fever, also called query fever, is a bacterial infection caused by the bacteria Coxiella burnetii. Common symptoms of Q fever include high fever, cough, headache, diarrhea, nausea, abdominal pain, jaundice and muscle pain. Risk factors include occupations. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Q Fever Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Q Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Q Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Q Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.Q Fever.

Q Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Q Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Q Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Q Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Q Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Q Fever (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Q Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Q Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Q Fever Overview 6
Therapeutics Development 7
Pipeline Products for Q Fever - Overview 7
Pipeline Products for Q Fever - Comparative Analysis 8
Q Fever - Therapeutics under Development by Companies 9
Q Fever - Therapeutics under Investigation by Universities/Institutes 10
Q Fever - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Q Fever - Products under Development by Companies 13
Q Fever - Products under Investigation by Universities/Institutes 14
Q Fever - Companies Involved in Therapeutics Development 15
Aradigm Corp 15
Grifols SA 16
Q Fever - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ARD-3100 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ARD-3150 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ciprofloxacin hydrochloride - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
NDBR-105 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Q Fever - Dormant Projects 38
Q Fever - Product Development Milestones 39
Featured News & Press Releases 39
Sep 20, 2012: UK Scientists Report Successful Testing Of Aradigm's Inhaled Liposomal Ciprofloxacin In Q Fever 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables
Number of Products under Development for Q Fever, H2 2016 7
Number of Products under Development for Q Fever - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Q Fever - Pipeline by Aradigm Corp, H2 2016 15
Q Fever - Pipeline by Grifols SA, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Q Fever - Dormant Projects, H2 2016 38

List of Figures
Number of Products under Development for Q Fever, H2 2016 7
Number of Products under Development for Q Fever - Comparative Analysis, H2 2016 8
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *